Acerca de EuroStemCell
EuroStemCell es un proyecto iniciado con el objetivo de ayudar a los ciudadanos europeos a entender qué son y cómo se utilizan las células madre. Facilitamos información imparcial y revisada por expertos, así como material didáctico probado en la práctica sobre las células madre y su repercusión en la sociedad. Para ello contamos con fondos del proyecto de investigación e innovación Horizonte 2020 de la Unión Europea (acuerdo de subvención número 652796). Puede encontrar más información sobre la historia de EuroStemCell aquí (en inglés).
Somos una alianza formada por más de 400 laboratorios de toda Europa especializados en investigación sobre células madre y en medicina regenerativa, todos ellos conectados a través de centros de investigación, consorcios y redes. Asimismo, participan en el proyecto científicos, expertos en medicina clínica, en ética y en ciencias sociales y especialistas en comunicación científica.
También colaboramos estrechamente con pacientes, profesionales de la educación, legisladores y responsables políticos, para fomentar la participación y para diseñar materiales que se ajusten a sus necesidades.
Nuestro equipo de proyectos, que tiene su sede en Edimburgo, reúne una amplia experiencia en el campo de la comunicación científica: desde la organización de actividades en escuelas y de cursos de formación hasta el desarrollo de materiales, la redacción de trabajos científicos, la realización de películas y la organización de eventos.
EuroStemCell cuenta con colaboraciones clave con consorcios de investigación de células madre financiados por la Unión Europea que contribuyen considerablemente al proyecto, tanto a nivel financiero como científico.
Las instituciones que nos apoyan
El trabajo sin fines de lucro de EuroStemCell es posible gracias al apoyo de estas instituciones asociadas
Professor Clare Blackburn is a Group Leader at the University of Edinburgh's Centre for Regenerative Medicine. EuroStemCell's Project Co-ordinator and Director of Training and Outreach for the original EuroStemCell, she has been instrumental in getting this website funded, up and running. She's also a Principal Investigator in Framework Seven project EuroSyStem.
Clare’s research focuses on development of the thymus. The thymus plays a central role in the development of the body’s immune system as it is the main site in which T cells are generated. T cells are a type of white blood cell that play an important role in immunity. Clare's lab recently identified a population of progenitor/stem cells in mice that, on transplantation, is sufficient to generate a fully functional thymus.
Amanda Waite is EuroStemCell’s Information, Network and Translation Manager and is based at the University of Edinburgh’s Centre for Regenerative Medicine. She coordinates EuroStemCell's network and manages the provision of expert-reviewed, reliable and accessible information about stem cells, including the translation of EuroStemCell’s website and resources.
Amanda joined the University in 2012 and worked in operations management, website development and system replacement projects before joining the EuroStemCell team. She has a Master of Professional Studies in Translation from the University of Auckland and has previously worked as a localisation project manager.
Anna Couturier is the Digital Manager for EuroStemCell and is based at the University of Edinburgh's Centre for Regenerative Medicine. She develops educational digital resources for EuroStemCell's partners and public. She also provides in-depth training for scientists and science communicators with a special focus on science and technology in digital spaces.
Michele de Luca
Michele de Luca
Professor De Luca, and his principal collaborator Graziella Pellegrini, have been involved in epithelial stem cell biology aimed at clinical application in regenerative medicine for over 20 years. Beside his work on the use of human epidermal stem cell cultures in life-saving treatment of massive full-thickness burns and in repigmentation of stable vitiligo and piebaldism, he established human limbal stem cell culture aimed at corneal regeneration in patients with severe limbal stem cell deficiency. This treatment leads to recovery of vision in patients with poor alternative options for therapy. Michele De Luca is currently coordinating the first (successful) ex-vivo epithelial stem cell-mediated gene therapy clinical trial for the gene therapy of junctional epidermolysis bullosa, a serious genetic skin disease. He is also studying molecular mechanisms regulating self-renewal, proliferative potential and clonal evolution of epithelial stem cells.
Professor Anne Rosser heads the South Wales clinical neurology service for HD as consultant neurologist. She chairs the UK HD research network and the UK arm of the European HD Network, and serves on the Scientific Advisory Committee of the global project Enroll-HD. As a scientist, Professor Rosser co-directs the Brain Repair Group in the Cardiff University School of Biosciences with particular responsibility for neural stem cell studies, and is the clinical director of the Cardiff Foetal Tissue Bank.
Sarah Chan is a recently-appointed Chancellor’s Fellow at the Usher Institute for Population Health Sciences and Informatics, University of Edinburgh. She was educated at the University of Melbourne, Australia, where she completed degrees in biological science and in law, and spent a number of years as a researcher in a molecular biology laboratory before moving to work in the area of science policy and stem cell ethics. In 2005 Sarah took up a Research Fellowship in Bioethics and Law at the Centre for Social Ethics and Policy, University of Manchester, where she also completed a MA in Health Care Ethics and Law and a PhD in Bioethics. From 2009 to 2015 she was Deputy Director of the Institute for Science, Ethics and Innovation, University of Manchester. Her research interests and publications cover areas including the ethics of gene therapy and genetic information, enhancement, research ethics, stem cells, animal ethics, transhumanism, and the ethics of science and innovation.
Hans Clevers is Principal Investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research (KNAW) and the Princess Máxima Center for pediatric oncology and also Professor of Molecular Genetics at the UMC Utrecht and Utrecht University, and Oncode Investigator.
Clevers discovered how the Wnt signaling pathway dictates cell fate decisions during animal embryogenesis by controlling gene expression. Looking beyond embryogenesis, he unveiled the role of Wnt signaling in colon cancer and in its physiological counterpart, the self-renewing gut epithelium. Combining these insights, he described the generic stem cell marker gene Lgr5, which has identified multiple novel adult stem cell types. Against prevailing views, these stem cells could be expanded indefinitely as organoids: mini-organs that recapitulate healthy or diseased human tissue in a dish. Organoids are rapidly gaining ground as research tools in a wide range of scientific disciplines including basic developmental and cell biology, infectiology, toxicology and research on hereditary diseases and cancer.
Christine Mummery is Professor and chair of Developmental Biology at Leiden University Medical Centre. She pioneered studies on cardiomyocytes from human embryonic stem cells and was among the first to inject them in mouse heart after myocardial infarction Present interests are on using stem cell derived cardiomyocytes and vascular cells as disease models, for drug discovery. In 2007, she was a joint Harvard Stem Cell Institute/Radcliffe fellow.
She presently serves on several Ethical Councils, Scientific Advisory and Editorial Boards and has written a popular book on stem cells. She is also on the board of ISSCR, president of the International Society of Differentiation and an elected member of the Royal Netherlands Academy of Science.
Oliver Brüstle is a neuropathologist and a renowned expert in stem cell research. Following research activities at the University of Zurich and the NIH in Bethesda, Maryland, he now serves as Professor of Reconstructive Neurobiology at the University of Bonn Medical Center.
Dr Cossu is the director of the Division of Regenerative Medicine at the San Raffaele Scientific Institute of Milan. His group has been working for a number of years on the signals and mechanism that regulate the formation of skeletal muscle during embryonic development and, after birth, when the muscle tissue is damaged as a result of an injury or a primary myopathy. He has developed a cell therapy protocol for muscular dystrophy.
Gerald de Haan
Gerald de Haan
Gerald holds the position of Scientific Director of the European Research Institute for the Biology of Ageing. The general scope of studies in his Laboratory is to further improve the understanding of mechanisms that specify normal stem cell functioning. Studies focus on hematopoietic stem cells, largely because superior technical tools and invaluable functional assays exist to study stem cells in this particular tissue. Gerald’s group is interested in the unique genetic and epigenetic program that distinguishes stem cells from non-stem cells.
Henrik Semb is Managing Director of Danstem and Professor of Human Stem Cell Biology. He uses an integrated and multi-disciplinary approach to his research which focuses on pancreas development and disease using a combination of developmental biology and stem cell research. He is the project co-ordinator of the EU funded HumEn project, which aims to up-scale the generation of insulin producing beta cells for the treatment of diabetes.
Thomas Graf is Coordinator of the Differentiation and Cancer Programme at the Center for Genomic Regulation and an ICREA professor in Barcelona, Spain. His lab is interested in the role of transcription factors in hematopoiesis and leukemia, and how these regulators can induce trans-differentiation. Is blood cell differentiation a strictly hierarchical process or does more than one pathway exist for the formation of a given cell type? More specifically, how does a single transcription factor, C/EBPa, reprogram B-lymphocytes to become functional macrophages? During this process, what epigenetic changes are required to turn thousands of genes off and on, making a 'cell within a cell'? What are the common principles during induced transdifferentiation? Answering some of these questions will enhance our understanding of the connection between differentiation and cancer. They will also help designing new protocols for the controlled reprogramming of differentiated cells that might be useful for cell replacement therapies.
Read an interview with Thomas Graf by Monya Baker of Nature Stem Cell Reports (requires subscription): Cellular Identity and Transdifferentiation
Professor Elena Cattaneo is Director of the Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases at the Department of Pharmacological Sciences, as well as a co-founder and first appointed Director of UniStem, the Centre for Stem Cell Research of the University of Milano. The main research theme of her lab is neural stem cells, and the molecular pathophysiology of Huntington’s Disease.
Funders of Prof Cattaneo's lab include the Huntington's Disease Society of America (H.D.S.A.), Hereditary Disease Foundation,High Q Foundation, the European Union (through EuroStemCell, NeuroStemcell, ESTOOLS, NeuroNE, STEM-HD and Stem-stroke projects), Fondazione Cariplo, and Telethon Italy.
Prof Cattaneo is a Coalition Investigator of the Huntington's Disease Society of America (H.D.S.A.), and a member of the Board of Directors of several European consortia (including EuroStemCell and NeuroNE). She acts as a reviewer for several journals (including Science, Nature Neuroscience, Nature Genetics, and Journal of Neuroscience) and international funding agencies, and is a member of the Scientific Advisory Board of the Hereditary Disease Foundation and of the Euro-HD Network.
Prof Cattaneo's studies on neural stem cells and Huntington's disease saw her awarded the “Le Scienze” Price for Medicine and a Gold Medal from the President of the Italian Republic in 2001. In 2005 she was awarded the Marisa Bellisario and Chiara D’Onofrio prizes, in 2006 was nominated Cavaliere Ufficiale (Knight) of the Italian Republic, and in 2013 was appointed senator for life by Italy's president, Giorgio Napolitano. She was also named Stem Cell Person of the Year in 2013 by Paul Knoepfler and the readers of his blog, and awarded the ISSCR Public Service Award in 2014, with Paolo Bianco and Michele De Luca, for "their recent involvement in public debate and policy-making in Italy, championing rigorous scientific and medical standards and stringent regulatory oversight in the introduction of new stem cell treatments into the clinic."
Prof Cattaneo has published 105 papers in peer-reviewed journals, has given more than 200 invited lectures, and is very active in organizing professional development and outreach events - for both the scientific community and lay public.
Maria Anna Ciemerych-Litwinienko
Maria Anna Ciemerych-Litwinienko
Maria A. Ciemerych is a developmental and cell biologist focusing on mammalian development, stem cells, and regenerative medicine. She completed her MSc and PhD at the Department of Embryology, Faculty of Biology, University of Warsaw, studying the initial stages and cell cycle regulation during preimplantation mammalian development. She continued to analyse early mouse embryo during her pre- and postdoctoral trainings at Manchester University, Welcome/CRC - University of Cambridge and Jacques Monod Institute - University Paris 7. Finally she moved for 3 years to Dana Farber Cancer Institute – Harvard Medical School, where she was focusing on cell cycle regulation not only in mouse embryos but also in stem cells. After her return to Warsaw, she got involved in the studies on skeletal muscle regeneration and myogenic differentiation of various stem cells, including embryonic stem cells and mesenchymal stem cells. In 2006 she became a head of the Department of Cytology, Faculty of Biology, University of Warsaw. For the last 4 years she has served as a dean for research at the Faculty of Biology, University of Warsaw. Being a scientist, she also actively popularises science during various outreach activities.
Paolo de Coppi
Paolo de Coppi
Paolo De Coppi is a Consultant Paediatric Surgeon at Great Ormond Street Hospital (GOSH), and Reader and Head of Stem Cells and Regenerative Medicine at the UCL Institute of Child Health in London.
He has been an Honorary Professor at the Katholieke Universiteit Leuven, Belgium, since 2013, an Adjunct Assistant Professor at the Wake Forest Institute for Regenerative Medicine, Wake Forest University in Winston-Salem, North Carolina, since 2009 and an Honorary Assistant Professor in Paediatric Surgery at the University of Padua, Italy, since 2005. He co-ordinates the EU Horizon2020 funded stem cell research consortium - INTENS which aims to aims to make a functional reconstructed bowel for people with Short Bowel Syndrome.
Prof. Andrews is Co-Director of the Centre for Stem Cell Biology at the University of Sheffield and leader of its Stem Cells and Cancer research group. The appearance of genetically abnormal cells aising from pluripotent stem cells in culture offers a unique model to study the initiation and progression of cancer cells. These models will allow the identification of critical genes which are responsible for the cancer-like properties of cells and may lead to novel strategies and therapies for treatment.
A/Prof Megan Munsie combines her extensive technical expertise with an interest and understanding of the complex ethical, social and regulatory issues associated with stem cell science. Megan heads the Education, Ethics, Law & Community Awareness Unit at the Australian Government funded Stem Cells Australia initiative. Megan is a member of an international research team that is exploring community expectation in relation to stem cell science, and in particular ‘stem cell tourism’. Over the last decade, Megan has contributed to the development of relevant policy in Australia and co-authored educational resources for the public and health professionals. In addition to having worked for over fifteen years in the Australian stem cell field, Megan also has more than ten years experience as an embryologist in IVF clinics around Australia.
Megan has a Bachelor of Applied Science from QUT, a Masters in Reproductive Sciences and a PhD from Monash University. It was during her PhD in 2000, in which she was the first person to demonstrate that stem cells could be made from ‘cloned' mouse embryos, that Megan saw the real need for scientists to engage with regulators and the public.
Göran Hermerén has been Professor of Medical Ethics at the Faculty of Medicine, Lund University, Sweden, since 1991. He has also held the position of Professor of Philosophy, Lund University, since 1975 and he was Professor of Philosophy of Science and Humanities, Umeå University from 1970-75. He is co-ordinator of the EU-funded research project Europriorities and is involved in several other EU-funded projects. He has published and edited books on research ethics as well as papers on ethical problems (mainly medical ethics) in international periodicals. Current research and teaching interests include ethical aspects of gene testing and stem cell research.
Professor Austin Smith FRS has expertise in the field of pluripotency and has pioneered key advances in the field of embryonic stem cell research. In 2010 he was awarded the prestigious Louis-Jeantet Prize for Medicine and in 2016 received the International Society for Stem Cell Research Award for Innovation. Austin was the Project Co-ordinator for the original EuroStemCell. You can view a short video describing Austin's research interests and motivations on the Louis-Jeantet Foundation website, and can visit his lab homepage at http://www.stemcells.cam.ac.uk/research/pis/smith
Fiona Watt obtained her DPhil from the University of Oxford, and carried out postdoctoral research at M.I.T, Cambridge, USA. She established her first lab at the Kennedy Institute of Rheumatology in London, and then moved to London Research Institute. From 2006 to 2012 she was Deputy Director of the Cancer Research UK Cambridge Research Institute and Deputy Director of the Wellcome Trust Centre for Stem Cell Research, University of Cambridge. She is currently Director of the Centre for Stem Cells and Regenerative Medicine, Kings College London. My major research interest is in the role of stem cells in adult tissue maintenance.
Andras is member of the Stem Cell Committee of the Hungarian Academy of Sciences, the Medical Research Council Committee on Human Reproduction and board member of the Hungarian Biotechnology Association. The Molecular Animal Biotechnology Laboratory of the Szent Istvan University, Hungary was established with his appointment as full professor. Furthermore, he is an invited professor at the Veterinary Faculty of Utrecht University, the Netherlands. He has an MBA-level degree in management and years of international experience in project and team management, and creation of industrial spin-offs via his role as co-founder and director of BioTalentum Ltd (www.biotalentum.eu). Prof. Dinnyes is member and advisor in several professional associations and society, and works as editor for the World Journal of Stem Cells and as Senior Editorial Board for the American Journal of Stem Cells. He was rewarded with the Gábor Dennis Innovation Award, Hungary in 2013.
Daniel Besser studied biology at the Freie Universität Berlin and obtained his diploma in 1990. He received his PhD in 1996 from the university of Basel with a thesis from the Friedrich-Miescher-Institute, Basel on signal transduction in the gene regulation of urokinase-type plasminogen activator. He worked at Rockefeller University, New York until 2004 in the laboratories of Hidesaburo Hanafusa and James E. Darnell on Stat3 signaling and the function of c-Src; and from 2002 on pluripotency in embryonic stem cells in the lab of Ali H. Brivanlou. He has been leader of a research group at the Max-Delbrück-Center for Molecular Medicine in Berlin until 2011 focusing his research on signal transduction mechanisms in human and murine embryonic stem cells.
Since 2012 he is managing director of the German Stem Cell Network (GSCN). The GSCN is fostering national and international scientific communications, as well as developing outreach programs for schools and the general public in Germany.
During Sílvia's PhD in Regenerative Medicine at the Center for Regenerative Therapies, Germany, she worked in Marius Ader's lab, using mouse embryonic stem cells to generate retinal organoids with the objective to obtain transplantable photoreceptors. Currently she is a PostDoc at the Center for Genomic Regulation (CRG), using human pluripotent stem cells to understand human germline development. She likes to be involved in symposium organisation and science communication activities.
Kate completed a PhD in the laboratory of Austin Smith in Cambridge, UK at the end of 2011. She studied rat embryonic stem cells and what makes them different from mouse embryonic stem cells; she hopes her work will help shed light on how to capture embryonic stem cells from other species. Kate’s high school biology teacher told her that if you can’t explain a piece of biology to your grandparents, you don’t really understand it.
Dr David Tosh leads the Vertebrate Embryonic Development research group at the Department of Biology and Biochemistry , University of Bath. His lab is interested in the phenomenon of transdifferentiation (sometimes referred to as metaplasia). Transdifferentiation is defined as the conversion of one differentiated cell type to another. It belongs to a wider class of cell type conversions known as metaplasias that include conversions between stem cell types.
The Tosh group has developed a number of models for the transdifferentiation of pancreas to liver and the reverse. They use their studies of transdifferentiation and metaplasia to help:
- Understand the normal developmental biology of the cells that interconvert.
- Help identify transcription factors that could be used to reprogram stem cells for therapeutic transplantation.
- Gain insight into how certain cancers develop.
Ruairi works as a Commercialisation Executive at NUI Galway, helping researchers in the regenerative medicine space to identify, protect and commercialise Intellectual Property emanating from their research. Ruairi has much experience regarding the patenting and commercialisation stem cells. Prior to his current position, he worked as a senior scientist with Stem Cell Sciences (Edinburgh) and completed his MBA dissertation on "the commercialisation of life science patents - a case study in embryonic stem cell research". Ruairi has a BSc from NUI Galway, a PhD from the University of Glasgow and an MBA from Edinburgh University.
I am a PhD student in Val Wilson's group, in the Centre for Regenerative Medicine, at the University of Edinburgh. I generate tools that will be used to understand how stem cells become specialized into specific cell types.
Prof. Alexander Medvinsky graduated from the Moscow State University, Department of Embryology in 1977 and obtained his PhD in the National Centre for Oncology, Moscow in 1987. In 1985 he started to work in the National Centre for Haematology, Moscow as a researcher and there he became interested in the development of haematopoietic stem cells (HSCs). In collaboration with colleagues, he identified a novel potent source of definitive haematopoietic activity inside the body of the embryo now called the AGM region and since then continues to work on the role of this organ in the development of HSCs. In 1993 he moved to the National Institute for Medical Research, London where he described important functional properties of the AGM region. In 1997 he accepted a group leader position in the Institute for Stem Cell Research and soon after that became an MRC Senior Fellow. In 2006 he was appointed as Professor in Haematopoietic Stem Cell Biology. The main focus of the Medvinsky laboratory "Ontogeny of Haematopoietic Stem Cells" is in understanding the mechanisms underlying the development of definitive HSCs.